NPS Pharmaceuticals About
NPS Pharmaceuticals NPS Pharmaceuticals is engaged in the discovery,
development, and commercialization of therapeutic small molecules and recombinant
proteins. Current products and product candidates include treatments for bone
and mineral disorders (osteoporosis
& hyperparathyroidism),
gastrointestinal disorders (GI) and central nervous system disorders (CNS). The
most advanced drug candidates being developed by NPS include PREOS® (recombinant
human parathyroid
hormone) for the treatment of osteoporosis,
and teduglutide for treating gastrointestinal disorders including
Short Bowel Syndrome, a condition in which much of the intestinal tract
has been surgically removed due to injury or disease resulting in inefficient
absorption of nutrients and fluids. Teduglutide has been granted orphan drug status
by both the Food and Drug Administration and the Commission of the European Communities
for this condition. Pipeline
for NPS Pharmaceuticals PREOS®
(recombinant human parathyroid hormone), Preotact, Calcilytics -- for the
treatment of osteoporosis
Teduglutide for treating gastrointestinal disorders including Short
Bowel Syndrome GlyT-1 - Schizophrenia
More Info on NPS Pharmaceuticals